A detailed history of Verition Fund Management LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 42,351 shares of ARWR stock, worth $814,409. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,351
Holding current value
$814,409
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $926,216 - $1.2 Million
42,351 New
42,351 $1.1 Million
Q3 2023

Nov 14, 2023

BUY
$26.2 - $36.08 $256,052 - $352,609
9,773 Added 98.4%
19,705 $529,000
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $249,889 - $410,986
9,932 New
9,932 $354,000
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $256,168 - $466,522
9,218 New
9,218 $325,000
Q1 2022

May 13, 2022

SELL
$39.62 - $69.97 $241,285 - $426,117
-6,090 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $353,768 - $502,485
6,090 New
6,090 $404,000
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $182,729 - $265,924
-3,130 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$62.15 - $90.32 $194,529 - $282,701
3,130 New
3,130 $259,000
Q4 2019

Feb 14, 2020

SELL
$28.14 - $73.01 $448,185 - $1.16 Million
-15,927 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$26.26 - $34.86 $418,243 - $555,215
15,927 New
15,927 $449,000
Q4 2018

Feb 14, 2019

SELL
$10.74 - $19.7 $207,861 - $381,273
-19,354 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$14.0 - $20.3 $270,956 - $392,886
19,354 New
19,354 $371,000
Q2 2018

Aug 15, 2018

SELL
$6.37 - $14.02 $219,268 - $482,596
-34,422 Closed
0 $0
Q1 2018

May 16, 2018

BUY
$3.72 - $7.64 $128,049 - $262,984
34,422 New
34,422 $248,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.04B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.